HAVCR2 and B-cell chronic lymphocytic leukemia: A more recent study reports that ex vivo treatment with ibrutinib increases cell viability and expansion of CLL patient-derived CAR-T cells, enriches CAR-T cells with less-differentiated naïve-like phenotype, decreases the expression of the exhaustion markers PD-1, TIM-3 and LAG-3, and enhances the cytokine release capacity of CLL patient-derived CAR-T cells (Fan et al., 2021).